CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference

Rhea-AI Summary

CVRx (NASDAQ: CVRX) has announced its upcoming participation in the Piper Sandler 36th Annual Healthcare Conference. The medical device company's management team is scheduled to deliver a presentation on Wednesday, December 4, 2024, at 3:30 PM Eastern Time. Interested parties can access a live audio webcast of the presentation through the investor relations section of CVRx's website at ir.cvrx.com.

News Market Reaction – CVRX

+9.25%

+9.25% Session move

In the trading session that priced this news, CVRX gained 9.25%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36^th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast.

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com.

About CVRx, Inc.

CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:

Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:

Laura O’Neill
Finn Partners
402-499-8203
laura.oneill@finnpartners.com

FAQ

When is CVRx presenting at the Piper Sandler Healthcare Conference 2024?

CVRx (NASDAQ: CVRX) is scheduled to present at the Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 3:30 PM Eastern Time.

How can I watch CVRx's presentation at the Piper Sandler Conference?

The presentation can be accessed via live audio webcast through CVRx's investor relations website at ir.cvrx.com.

Which healthcare conference is CVRx participating in December 2024?

CVRx is participating in the Piper Sandler 36th Annual Healthcare Conference in December 2024.

Will CVRx's Piper Sandler Conference presentation be available online?

Yes, CVRx's presentation will be available through a live audio webcast on the investor relations page of their website at ir.cvrx.com.